Vutiglabridin
Small molecule
Also known as HSG4112
Evidence outlook · lead readout
NCT06329141 · Parkinson Disease
The completed lead evidence is positive, with design limits that temper confidence; the rationale below says which.
NCT06329141: The randomized, placebo-controlled Phase 2 trial in early Parkinson's disease randomized 99 participants. In the per-protocol analysis (77 participants), the 800 mg dose improved the MDS-UPDRS Part III score by 3.56 points against placebo (P = .03); the intention-to-treat result is not reported.
Caveat: result from a company announcement and a conference presentation, in the per-protocol population (77 of 99 randomized); not from the registry or a peer-reviewed publication.
Also in development:Osteoarthritis · Phase 2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT06329141 NCT06329141 · Parkinson Disease The randomized, placebo-controlled Phase 2 trial in early Parkinson's disease randomized 99 participants. In the per-protocol analysis (77 participants), the 800 mg dose improved the MDS-UPDRS Part III score by 3.56 points against placebo (P = .03); the intention-to-treat result is not reported. Caveat: result from a company announcement and a conference presentation, in the per-protocol population (77 of 99 randomized); not from the registry or a peer-reviewed publication. Registry: NCT06329141 | 2 | Change From Baseline in MDS-UPDRS Part III Subscore (From baseline to Week 24) 2025-12-16 | Results not posted; external-source review pending | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (3)
What this study did
What this study did
What this study did
Phase 1 (4)
What this study did
What this study did
What this study did
What this study did
Competitive landscape
This drug's own stage for Osteoarthritis: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Vutiglabridin: this drug | Phase 2 | Small molecule | paraoxonase-2 (PON2) | not yet graded | No reviewed efficacy summary in this indication | |
| Ecnoglutide | Phase 3 | Peptide | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Eloralintide | Phase 3 | Peptide | Amylin receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Orforglipron (Foundayo) | Phase 3 | Small molecule | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Allocetra | Phase 2 | Cell therapy | Macrophage reprogramming | not yet graded | No reviewed efficacy summary in this indication | |
| PLX-PAD | —(overall) | Cell therapy | Mesenchymal stem cells (immunomodulatory, pro-angiogenic) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.